E-Mail
The risk of both mortality and rehospitalisation after an elective revascularisation procedure for coronary artery disease is similar for people with and without Alzheimer s disease (AD), but people with AD had worse outcomes after an emergency procedure, according to a new study from the University of Eastern Finland.
Previous studies have investigated the effectiveness of revascularisation in persons with cognitive disorders, but only in terms of short-term outcomes and in acute care settings, and they also have not accounted for electivity. Similar to previous studies, people with Alzheimer s disease were 76% less likely to undergo a revascularisation procedure and only a third of the procedures were elective, compared to 48.6% of elective procedures in the comparison group without AD.
A new study found that treating obstructive sleep apnea with CPAP therapy increased self-reported physical activity in adults with a history of heart disease.
E-Mail
Canadian researchers are the first to study how different patterns in the way older adults walk could more accurately diagnose different types of dementia and identify Alzheimer s disease.
A new study by a Canadian research team, led by London researchers from Lawson Health Research Institute and Western University, evaluated the walking patterns and brain function of 500 participants currently enrolled in clinical trials. Their findings are published today in
Alzheimer s & Dementia: The Journal of the Alzheimer s Association. We have longstanding evidence showing that cognitive problems, such as poor memory and executive dysfunction, can be predictors of dementia. Now, we re seeing that motor performance, specifically the way you walk, can help diagnose different types of neurodegenerative conditions, says Dr. Manuel Montero-Odasso, Scientist at Lawson and Professor at Western s Schulich School of Medicine & Dentistry.
Date Time
Neuren Pharmaceuticals updates on phase one trial
Australian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one trial of its twice-daily oral investigative therapy NNZ-2591 found it was safe and well-tolerated for seven days.
The company said the data will form part of its planned Investigational New Drug (IND) application to the US FDA in preparation for phase two trials in Phelan McDermid, Angelman and Pitt Hopkins syndromes.
Neuren CEO Jon Pilcher said, “This trial was the first human dosing for NNZ-2591 and we are very pleased with the outcome. Twice daily oral dosing for seven days was safe and well-tolerated at doses we expect to be within the effective therapeutic range, which gives us confidence for dosing patients in our planned Phase 2 trials.”
Researchers from Skoltech and their colleagues have demonstrated that nanoengineered biodegradable microcapsules can guide the development of hippocampal neurons in an in vitro experiment. The microcapsules deliver nerve growth factor, a peptide necessary for neuron growth.